Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.37 |
| ▸ | CES1 | P23141 | 3/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9712517 | 0.83 | CES2 (0.31) | CES2CES1 | |
| SCHEMBL566436 | 0.78 | SELL (0.32) | TRPV4 | |
| SCHEMBL9712347 | 0.78 | TSHR (0.35) | TRPV4 | |
| SCHEMBL2951474 | 0.78 | TRPV4 (0.31) | TRPV4 | |
| SCHEMBL23877898 | 0.74 | CYP1A1 (0.31) | — | |
| SCHEMBL7300875 | 0.72 | TAAR1 (0.45) | ALDH1A1CA12CA1CA9 | |
| SCHEMBL2336780 | 0.71 | TRPV4 (0.33) | CES2CES1ERN1TRPV4ALDH1A1 | |
| SCHEMBL3974422 | 0.71 | CA1 (0.39) | CES2CES1CA12CA1 | |
| SCHEMBL18245169 | 0.71 | TRPV4 (0.33) | CES2CES1ERN1TRPV4ALDH1A1 | |
| SCHEMBL95707 | 0.71 | CES2 (0.42) | CES2CES1ERN1DAOALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6150378-A | 1-((1-HALO-SUBSTITUTEDBENZOYLAMINO)-2-PHENYLETHYL)-CARBONYL -CARBONYLAMINO),2-PHENYL OR PYRID-2-YLSULFAMIDO)ETHANE DERIVATIVES; MUSCULAR DYSTROPHY, NEURODEGENERATION, STROKE, ALZHEIMER'S, AMYOTROPHY, MOTOR NEURON DAMAGE, CNS INJURY | CEPHALON, INC. (US) | 2000-11-21 | — | — | US | claimed |
| EP-4073056-B1 | PROCESS FOR THE PREPARATION OF LASMIDITAN AND OF A SYNTHESIS INTERMEDIATE | OLON SPA (IT) | 2024-04-17 | — | — | EP | disclosed |
| US-11939301-B2 | 5HT1F receptor agonists and mitochondrial biogenesis | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2024-03-26 | — | — | US | disclosed |
| US-20210238147-A1 | 5HT1F RECEPTOR AGONISTS AND MITOCHONDRIAL BIOGENESIS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT | 2021-08-05 | — | — | US | disclosed |
| US-11014892-B2 | 5HT1F receptor agonists and mitochondrial biogenesis | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200055827-A1 | 5HT1F RECEPTOR AGONISTS AND MITOCHONDRIAL BIOGENESIS | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2020-02-20 | — | — | US | disclosed |
| US-9608287-B2 | Non-aqueous electrolytic solution, electrical storage device utilizing same, and cyclic sulfonic acid ester compound | UBE INDUSTRIES, LTD. (JP) | 2017-03-28 | — | — | US | disclosed |
| EP-2462959-B1 | Methods and products for treatment of diseases | AMPIO PHARMACEUTICALS INC (US) | 2016-06-22 | — | — | EP | disclosed |
| US-9318776-B2 | Nonaqueous electrolyte solution and electricity storage device using same | UBE INDUSTRIES, LTD. (JP) | 2016-04-19 | — | — | US | disclosed |
| US-20150372349-A1 | NON-AQUEOUS ELECTROLYTE AND ELECTRICITY STORAGE DEVICE | UBE INDUSTRIES, LTD. (JP) | 2015-12-24 | — | — | US | disclosed |
| EP-1021199-A4 | PEPTIDE-CONTAINING $g(a)-KETOAMIDE CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON INC (US) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002057264-A1 | PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES | SANKYO COMPANY LIMITED (JP) | 2002-07-25 | — | — | WO | disclosed |
| US-6288231-B1 | ENZYME INHIBITORS | CEPHALON, INC. | 2001-09-11 | — | — | US | disclosed |
| US-6150378-A | 1-((1-HALO-SUBSTITUTEDBENZOYLAMINO)-2-PHENYLETHYL)-CARBONYL -CARBONYLAMINO),2-PHENYL OR PYRID-2-YLSULFAMIDO)ETHANE DERIVATIVES; MUSCULAR DYSTROPHY, NEURODEGENERATION, STROKE, ALZHEIMER'S, AMYOTROPHY, MOTOR NEURON DAMAGE, CNS INJURY | CEPHALON, INC. (US) | 2000-11-21 | — | — | US | disclosed |
| EP-1021199-A1 | PEPTIDE-CONTAINING $g(a)-KETOAMIDE CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON, INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999017790-A1 | PEPTIDE-CONTAINING α-KETOAMIDE CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON INC. (US) | 1999-04-15 | — | — | WO | disclosed |
| US-5436242-A | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof for inhibiting blood platelet aggregation | SANKYO COMPANY, LIMITED (JP) | 1995-07-25 | — | — | US | disclosed |
| US-5288726-A | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation | UBE INDUSTRIES LIMITED (JP) | 1994-02-22 | — | — | US | disclosed |
| EP-0542411-A2 | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation | Sankyo Company Limited (JP) | 1993-05-19 | — | — | EP | disclosed |
| US-4021248-A | SILVER HALIDE | FUJI PHOTO FILM CO., LTD. (JA) | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939301-B2 | 5HT1F receptor agonists and mitochondrial biogenesis | HTR1F, HTR1A, TFAM | CES2 4213/4885CES1 2716/4885ERN1 3284/4885 |
| US-11014892-B2 | 5HT1F receptor agonists and mitochondrial biogenesis | HTR1F, HTR1A, TFAM | CES2 4213/4885CES1 2716/4885ERN1 3284/4885 |
| US-20200055827-A1 | 5HT1F RECEPTOR AGONISTS AND MITOCHONDRIAL BIOGENESIS | HTR1F, HTR1A, TFAM | CES2 4213/4885CES1 2716/4885ERN1 3284/4885 |
| US-20150372349-A1 | NON-AQUEOUS ELECTROLYTE AND ELECTRICITY STORAGE DEVICE | HCN2, SCO2, HCN1 | CES2 83/4885CES1 624/4885ERN1 96/4885 |
| US-20210238147-A1 | 5HT1F RECEPTOR AGONISTS AND MITOCHONDRIAL BIOGENESIS | HTR1F, HTR1A, TFAM | CES2 4213/4885CES1 2716/4885ERN1 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.